KOSDAQBiotech & Pharma214370

Caregen

₩26,800▼ 0.19%2026-11-18 close
Market Cap
₩1.4T
Turnover
₩2.1B
Volume
80K
Shares out.
53.7M
PER
103.1×
PBR
6.6×
EPS
₩273
Dividend Yield
1.55%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩437 per share · Prices as of the 2026-11-18 close

01

Report overview

Caregen: Testing Overseas Sales Growth Amid Volatile Profits

Caregen posted KRW 22.7 billion in revenue and KRW 10.2 billion in operating profit in Q1 2026, but net profit attributable to controlling shareholders has declined for two straight quarters since, leaving overseas health-supplement sales as the key test.

  1. 1

    On a disclosed basis, operating profit peaked at KRW 40.4 billion in 2023, then fell for two consecutive years in 2024 and 2025, with the 2025 operating margin at 28.0%.

  2. 2

    Q1 2026 was the peak of the period shown, with KRW 22.7 billion in revenue and KRW 11.7 billion in net profit attributable to controlling shareholders; revenue and that profit line both declined in Q2 and Q3, when controlling-shareholder net profit was KRW 648 million.

  3. 3

    Health supplements are emerging as the overseas growth engine; press reports put Q2 2026 health-supplement revenue at KRW 5.5 billion, up from KRW 0.3 billion a year earlier.

  4. 4

    The 2026 value-enhancement plan disclosed in March targets annual operating profit growth of at least 5% and a dividend payout ratio of at least 30%.

  5. 5

    The share price sits well above the last four quarters of controlling-shareholder net profit (KRW 13.4 billion) and year-end 2025 book equity (KRW 212.5 billion), so the pace of profit recovery is the central variable.

02

Business structure

Caregen is a biotech company that builds cosmetic ingredients, fillers, health supplements and drug candidates on peptide technology. The company says it holds roughly 960 substance patents at home and abroad, as stated after its CPHI Milan appearance in October 2026.

The company attributed the 2025 revenue decline to a renewal of its core filler product line and a reallocation of supply regions. Its health-supplement lineup centers on Korglutide, Myoki and ProGsterol.

Korglutide is a GLP-1-based peptide presented as a product that can help offset muscle loss alongside weight reduction, and it has entered the U.S. market after FDA NDI registration. Press reports say Myoki completed registration with Mexican health authorities.

On the platform side, the proprietary delivery technology Luxidase is central, and a topical siRNA hair product built on it was shown at CPHI Milan. Representatives of global cosmetics companies including Estée Lauder visited the booth to discuss technology licensing.

On the drug side, press reports in August 2026 described the eye-drop wet AMD candidate CG-P5 as having entered Phase 2, while the next-generation CG-T1 is being prepared for global clinical entry.

Sales run through overseas distribution partners; in May 2026, a supply contract worth USD 5.7 million for ProGsterol with a Polish company was reported. Within the sector, peptide-based listed companies such as Peptron and SAM Chun Dang Pharm serve as reference points.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17.1B₩9.9B57.7%
2025Q4₩16.3B-₩7.1B−43.4%
2026Q1₩22.7B₩10.2B45.0%
2026Q2₩18.8B₩5.2B27.9%
2026Q3₩18.4B₩7.2B39.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩69.1B₩33.6B₩27.3B48.7%12.6%8.4%
2023₩79.2B₩40.4B₩39.9B51.0%17.6%8.8%
2024₩82.6B₩34.2B₩32.3B41.5%14.5%7.9%
2025₩72.8B₩20.4B₩20.1B28.0%9.5%8.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 69.1 billion in 2022 to KRW 79.2 billion in 2023 and KRW 82.6 billion in 2024, then fell 11.8% to KRW 72.8 billion in 2025. Within 2022 to 2025, 2024 was the largest year and 2022 the smallest.

Operating profit peaked at KRW 40.4 billion in 2023, then fell to KRW 34.2 billion in 2024 and KRW 20.4 billion in 2025, two consecutive years of decline, and the operating margin slid from 48.7% in 2022 and 51.0% in 2023 to 41.5% in 2024 and 28.0% in 2025.

The company attributed the 2025 revenue decline to the renewal of its core product lines and a reallocation of supply regions to improve profitability.

The same year, a conservative bad-debt provision reflecting Middle East tensions and foreign-currency valuation gains and losses tied to a weaker exchange rate weighed further on earnings.

As a result, net profit attributable to controlling shareholders fell 37.8% to KRW 20.1 billion in 2025, and total net profit including non-controlling interests was also KRW 20.1 billion. For the 2024 operating profit decline, the company pointed mainly to higher R&D spending.

Quarterly, Q4 2025 swung to an operating loss of KRW 7.07 billion and a net loss attributable to controlling shareholders of KRW 3.28 billion.

Q1 2026 returned to profit with KRW 22.7 billion in revenue, KRW 10.2 billion in operating profit and KRW 11.7 billion in controlling-shareholder net profit, the peak of the period shown.

Q2 2026 revenue was KRW 18.8 billion with operating profit of KRW 5.24 billion, and Q3 2026 revenue was KRW 18.4 billion with operating profit of KRW 7.19 billion. Q3 operating profit rose 37.3% from the prior quarter but fell 27.1% year on year.

Controlling-shareholder net profit was KRW 648 million in Q3, down 93.6% year on year, and the last four quarters combined total KRW 13.4 billion. In its Q2 announcement, the company had flagged deferred European sales and a bad-debt provision reversal for Q3, yet Q3 revenue was 2.2% lower than in the prior quarter.

05

Industry analysis

Peptides are a technology trend with expanding uses across cosmetics, medical devices, health supplements and drugs, and CEO Jeong Yong-ji said the trend was confirmed firsthand at CPHI Milan.

In health supplements, GLP-1-type peptide ingredients are drawing attention for demand around weight management and muscle support. European entry depends on novel-food approval, and a May 2026 report said Deglusterol is in the final stage of evaluation by the European Food Safety Authority.

In the United States, FDA NDI registration serves as the entry base, and the company says it has secured this. On competition, Thinkpool analysis of Q1 2026 said Caregen's revenue growth trailed peers while its operating profit growth ran relatively high.

Geopolitics also shapes the backdrop: in Q2 2025, supply chains for ProGsterol were temporarily constrained by the spillover from the Iran-Israel war. Trade shows and conferences serve as channels for overseas demand, and Caregen participated as an emerald sponsor at IMCAS, the large aesthetic medicine congress.

In fillers, the company competes with global medical aesthetics firms, so whether the product line renewal translates into market share is the key question.

06

Outlook

The company's medium-term targets appear in its 2026 value-enhancement plan, which calls for annual operating profit growth of at least 5% and a dividend payout ratio of at least 30%; it was disclosed on March 24, 2026.

CEO Jeong Yong-ji described 2026 as the first year of a shift to global growth and said that from the second quarter, the U.S. launch of Korglutide and sales expansion of Luxidase-based products would take hold.

A capacity expansion is also planned: in April 2026, the CEO told Paxetv that production capacity, now around 10 tons a year, would be raised to 30 to 50 tons. In Europe, EFSA approval of Deglusterol is the gate, and the company said it is preparing a supply system for immediate entry after approval.

In the pipeline, press reports from August 2026 said the eye-drop candidate CG-P5 entered Phase 2, while CG-T1 is preparing for global clinical entry.

At its September 2026 global partners meeting, the company said it would pursue commercialization of new products linking functional peptides with RNA delivery technology, along with management of its export supply chain.

However, on disclosed figures revenue and controlling-shareholder net profit have trended lower through Q3, so the speed at which overseas sales growth shows up in quarterly results is the next checkpoint.

Comparison of the 2026 fiscal-year outcome against the plan will be possible with the annual report around late March 2027.

07

Valuation

PER
103.1×
PBR
6.6×
ROE
6.3%
EPS
₩273
BPS
₩4,281
Dividend per share
₩437

The market value is large relative to earnings. Against the last four quarters of controlling-shareholder net profit totaling KRW 13.4 billion, market capitalization is more than 100 times that figure.

On book value, market capitalization is more than seven times year-end 2025 total equity of KRW 212.5 billion, a large premium over net assets. When earnings have shrunk, the earnings multiple rises sharply even at a constant share price, so the multiple is highly sensitive to the pace of profit recovery.

The 2026 plan calls for a dividend payout ratio of at least 30%, which ties per-share dividends to the earnings trend. The largest shareholder and related parties hold 64.47% and the free float ratio is 26.47% as of September 2026, so the shares available for trading are relatively limited.

In short, the share price sits in a zone that is large relative to earnings and book equity, and how the multiple changes as profit recovers is the next point to watch.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

High-margin profile

On disclosed figures, the operating margin stayed above 40% through 2024. The company announced an operating margin of about 45% for Q1 2026 and described it as industry-leading profitability. Q1 2026 revenue of KRW 22.7 billion and operating profit of KRW 10.2 billion marked the peak of the period shown.

Overseas expansion of health supplements

Press reports put health-supplement revenue at KRW 5.5 billion in Q2 2026, up from KRW 0.3 billion a year earlier. Korglutide entered the U.S. market stage after FDA NDI registration, and Myoki's registration with Mexican health authorities was reported. In May 2026, a USD 5.7 million ProGsterol supply contract with a Polish company was reported.

Platform technology and patent base

The company says it holds around 960 substance patents and filed 238 patents in 2025. A topical siRNA hair product based on Luxidase was shown at CPHI Milan, and representatives of global cosmetics firms including Estée Lauder discussed technology licensing. Contracts with partners in some countries were reportedly signed on site.

09

Bear factors

Declining operating profit trend

Operating profit fell from KRW 40.4 billion in 2023 to KRW 20.4 billion in 2025, with declines in both 2024 and 2025. The 2025 operating margin of 28.0% is well below the 48.7% of 2022. Controlling-shareholder net profit in Q3 2026 was KRW 648 million, down 93.6% year on year.

Revenue volatility and past quarterly losses

Revenue fell 11.8% to KRW 72.8 billion in 2025, and Q4 2025 swung to an operating loss of KRW 7.07 billion. Revenue declined in both Q2 and Q3 2026. Q2 operating profit fell 48.7% from the prior quarter, reversing much of the Q1 peak.

Large market value versus earnings and concentrated ownership

Market capitalization exceeds 100 times the last four quarters of controlling-shareholder net profit and more than seven times year-end 2025 total equity. The largest shareholder and related parties hold 64.47%, and the free float ratio is 26.47%. The bear case holds that if profit recovery is delayed, the earnings-multiple burden could persist.

10

Risk factors

Supply chain and geopolitics

In Q2 2025, ProGsterol supply was disrupted by the spillover from the Iran-Israel war. In 2025, a conservative bad-debt provision reflecting Middle East instability weighed on earnings. Middle East variables affect revenue recognition, receivable collection and supply timing together.

Regulatory and clinical timing uncertainty

European entry for Deglusterol depends on EFSA novel-food approval, and CG-P5 is in Phase 2. Neither the approval timing nor the clinical readout timing is fixed, which leaves earnings visibility uncertain.

The speed at which overseas supply contracts flow into quarterly results remains to be seen in the reported figures.

Ownership structure and liquidity

Jeong Yong-ji and five related parties hold 64.47% of issued shares as of September 2026. The free float ratio is 26.47% and the 52-week beta is recorded at 1.31, a relatively wide price swing against the market. A concentrated ownership structure can affect trading volume and price formation.

11

What to watch next

  1. After December 2026 (date to be confirmed)

    Whether EFSA grants novel-food approval for Deglusterol. It is the point at which European supply and partnership contracts could begin to show up in results.

  2. Around late March 2027

    The 2026 fiscal-year annual report and full-year results. It is where the plan of at least 5% annual operating profit growth and a payout ratio of at least 30% gets tested against actual figures. The 2025 fiscal-year results were disclosed on March 13, 2026.

  3. Around late April 2027

    Q1 2027 results. The Q1 2026 results were announced on April 30. It is where the company's quarterly revenue trend, including overseas health-supplement sales, can be checked.

  4. First half of 2027 (date to be confirmed)

    Interim results from the CG-P5 wet AMD Phase 2 trial and whether CG-T1 enters global clinical testing. It is where drug pipeline progress can be assessed separately from the health-supplement business.

  5. After December 2026 (date to be confirmed)

    Whether a large Korglutide supply contract centered on the United States is signed. The CEO has said a major contract was close, so its size and timing of revenue recognition are the points to verify.

12

Overall view

On disclosed figures, Caregen's operating profit and controlling-shareholder net profit have declined since their 2023 peak, and quarterly results have been volatile in 2026.

Q1 2026 revenue of KRW 22.7 billion and operating profit of KRW 10.2 billion marked the high point of the period shown, and revenue and controlling-shareholder net profit then declined in both Q2 and Q3.

The bullish factors are the historically high-margin profile, the expansion of overseas channels for health supplements, the patent base and delivery platform, and partner contracts already signed.

The bearish factors are the downward operating margin trend, the record of quarterly losses, Middle East and other geopolitical variables, and a market value that is large relative to earnings. Both sets of factors currently carry comparable weight, so the disclosed figures alone do not settle the direction.

The 2026 value-enhancement plan targets at least 5% annual operating profit growth, and the gap between that plan and actual results will serve as the medium-term benchmark. The next checkpoints are the 2026 fiscal-year results and EFSA approval for Deglusterol.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. venturesquare.net
  3. pharmnews.com
  4. digitaltoday.co.kr
  5. thevc.kr
  6. m.news.nate.com
  7. m.thinkpool.com
  8. thebionews.net
  9. pharmnews.com
  10. hitnews.co.kr
  11. news.nate.com
  12. sale.mimint.co.kr
  13. pharmnews.com
  14. biotimes.co.kr
  15. paxetv.com
  16. pinpointnews.co.kr
  17. kndaily.co.kr
  18. alphasquare.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis